Comparative Pharmacology
Head-to-head clinical analysis: KERYDIN versus MONISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERYDIN versus MONISTAT.
KERYDIN vs MONISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KERYDIN (tavaborole) is a boron-based antifungal that inhibits fungal protein synthesis by blocking the activity of leucyl-tRNA synthetase, thereby preventing aminoacylation of tRNA(Leu) and impairing protein synthesis in dermatophytes.
Miconazole, the active ingredient in MONISTAT, inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity, leading to cell death.
8 mg/kg (max 800 mg) IV over 2 hours once daily for 14 days
Intravaginal: 200 mg suppository at bedtime for 3 days, or 100 mg suppository at bedtime for 7 days, or 2% cream 5 g intravaginally at bedtime for 7 days. Topical: Apply 2% cream twice daily for 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily topical application.
Approximately 90-120 minutes; supports twice-daily local dosing.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 88% of the dose, with negligible fecal excretion (<1% as unchanged drug).
Primarily fecal (approximately 90%) as unchanged drug; less than 2% renal elimination.
Category C
Category C
Antifungal
Antifungal